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Extracorporeal membrane oxygenation (ECMO) in the veno-arterial (VA) configuration is an established 
method for the treatment of refractory cardiogenic shock. Such a condition characterizes the postoperative 
course of approximatively 1% of cardiac surgery patients. Although some studies have reported ECMO-
related short-term results, little is known about the long-term outcomes of VA-ECMO therapy in the post-
cardiotomy setting. Therefore, an extensive literature search was conducted regarding articles published 
after 1990 reporting postoperative ECMO use. PubMed, EMBASE and Web of Science were searched for 
sources. In-hospital mortality was high in post-cardiotomy VA-ECMO patients, ranging from 24.8% to 
52%. Long-term results were poorly reported. However, based on the limited information available, hospital 
survivors showed a favorable outcome, with improvement in overall clinical condition, quality of life and 
limited hospital readmission for cardiac-related events. To conclude, in-hospital outcome in post-cardiotomy 
ECMO is often unfavorable, post-discharge results show satisfactory condition, with stable improvement 
of overall patient clinical status and low rate of hospital readmission and cardiac-related adverse events. 
Data reporting is, however, scarce and hence new and detailed studies are still warranted to investigate such 
aspects.
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Perspective
Introduction
Since the first implantation by Hill and colleagues (1), 
extracorporeal membrane oxygenation (ECMO) has 
become an established treatment option for adult patients 
with refractory cardiogenic shock (2), providing temporary 
cardiac and respiratory support. Approximately 1% of 
adult patients who undergo cardiac surgery develop post-
cardiotomy cardiogenic shock (PCS) and require mechanical 
circulatory support (MCS) beyond the conventional 
medical or mechanical treatments to support the failing 
heart (1-5). Because of its quick availability, easy and rapid 
applicability and reliability, ECMO support has become 
a more and more attractive option, particularly in post-
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cardiotomy (PC) setting (1-3). Another option available is 
short-term ventricular assist devices (VADs), either uni- or 
biventricular, but complexity, lack of lung support, and costs 
has limited its wide application (6-8).
PC-ECMO has become the most frequent indication for 
ECMO in the United States (3), however, its exponential 
increase has not been paralleled by improved results, but 
rather to the contrary (5). Although during the last 20 years 
advances in technique and management were achieved, 
ECMO results have not been satisfactory. Prevalence, 
trends of use, indications and implant information, types 
of patient, specific procedures for whom it is being used, 
in-hospital patient management and short- and long-term 
outcomes have peculiar features in the PC-ECMO setting. 
Information on post-hospital discharge outcomes after 
veno-arterial (VA)-ECMO (ranging from 1 year to 10 years) 
have shown overall survival rates ranging from 17% to 40% 
(9-11), but little attention has been given to other factors 
related to the long-term prognosis (12-14). Furthermore, 
despite numerous publications that have shown ECMO-
related short and medium-term results, specific reports 
about PC-ECMO have been limited and usually related 
to single-center experience. In addition, some reports 
have shown some critical illness in survivors, with some 
long-term functional impairment in physical, cognitive 
and psycho-social settings (15,16). A targeted analysis of 
these aspects would have a relevant implication in the daily 
practice of ECMO users. This review, therefore, had the 
aim to present the current information about PC-ECMO 
in adult patients, providing an evaluation of the long-term 
mortality and morbidity for VA-ECMO.
Methods
A literature search was run on PubMed, EMBASE and Web 
of Science covering the time period between January 1990 
and August 2018. Publications that appeared before 1990 
were not included due to the remarkable dissimilarity in 
intensive care unit management, surgical techniques and 
ECMO-related technology. Two operators independently 
performed the computerized literature search using 
the following keywords: “Postoperative extracorporeal 
membrane oxygenation”, “Postoperative extracorporeal 
l i f e  support” ,  “Pos t -Card iotomy” ,  “Mechanica l 
Circulatory Support”, “Temporary Mechanical Circulatory 
Support”, “Perioperative Cardio-Pulmonary Assistance”, 
“Perioperative Cardio-Pulmonary Failure”, “Percutaneous 
Mechanical Circulatory Support”,  “Postoperative 
Cardiogenic Shock”, “Postoperative Cardiac Arrest”, “Post-
cardiotomy Cardiac Arrest”, “Post-Cardiotomy Cardiac 
Failure”, “Post-Cardiotomy Complications”, “ARDS 
and cardiac surgery”, “Post-Cardiotomy Respiratory 
Dysfunction”. Information regarding target populations, 
ECMO implantation site and major outcomes were 
collected and systematically recorded. Only publications in 
English were considered.
Only studies specifically conducting on ECMO in peri- 
or post-operative adults (>18 years of age) undergoing 
cardiac surgery (see Table 1) were collected, leading to a 
careful assessment of short-term outcomes and evaluation 
of post-discharge follow-up. Exclusion criteria included 
published PC-ECMO series, case reports, or case series, 
reporting less than 10 patients, as these would not allow for 
a meaningful cohort analysis of PC-ECMO patients.
Results
Overall, 242 published papers were selected, reviewed and 
carefully analyzed. The flow-chart showing the literature 
search and selection for final information analysis is shown 
in Figure 1. Table 1 shows the main results. Fifteen studies 
were selected, included 2,852 patients supported with VA-
ECMO due to PCS. The mean age was 63.7 years. VA-
ECMO was placed using central and peripheral cannulation. 
In-hospital survival ranged from 24.8% to 52%, whereas 
1-year survival ranged from 16.5% to 47.6%. Regarding 
long-term survival, the best rate reported was 37% 
(Table 1). However, each study has considered different 
timing, therefore any consistent and comprehensive 
evaluation was not feasible. A total of six articles, enrolling 
2,033 patients, reported 5-year survival, while only two 
studies (1,188 subjects) provided data for 10-year survival. 
Corresponding reported survival ranged from 13.7% to 
32% and from 9.7% to 17.6%, respectively. The created 
variable regarding the survival difference, representing 
the difference between one-year and in-hospital survival, 
ranged from 0% to 21%, thereby confirming that long-
term mortality was relatively low in these patients, although 
these findings were hampered by the maximum follow-up at 
10 years from the original operation.
Table 2 shows the described major outcomes found in 
this literature selection. These mainly consisted of five 
fields reported: New York Heart Association Class, re-
hospitalizations, medical expenditures, quality of life and 
specific outcomes regarding dead and survived patients. 
From the limited data and information available, it is 
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Table 1 Postcardiotomy ECMO studies
Author reference Year of publication Patient Mean age (years) In-hospital survival (%) 1-year survival (%) Long-term survival (years) (%)
Magovern (17) 1994 21 61.6±2.2 52 47.6 NA
Kodera (18) 1996 17 41.4 47.1 NA 5 (30.9)
Ko (19) 2002 76 56.8±15.9 26.3 45.4 2.7 (23.0)
Doll (20) 2004 219 61.3±12.1 24 NA 5 (16.8)
Zhang (21) 2006 32 55.4±11.9 25 NA 3.8 (12.5)
Bakhtiary (22) 2008 45 60.1±13.6 29 29 3 (22.0)
Hsu (23) 2010 51 63±15.7 24.8 16.5 NA
Rastan (24) 2010 517 63.5±11.2 30.4 NA 5 (13.7)
Unosawa (25) 2013 47 64.4±12.5 40.3 24.5 3 (27.7)
5 (20.1)
10 (17.6)
Saxena (26) 2015 45 76.8±4.6 24.4 24.4 3 (17.7)
Khorsandi (27) 2016 16 71 51 29.8 2 (31.0)
Distelmaier (28) 2016 385 65 32 NA 3.6 (32.0)
Chen (29) 2017 1,141 63.8±13.2 38.3 24.1 5 (17.7)
10 (9.7)
Guihaire (30) 2017 92 64.5 42 39 2 (37.0)
5 (32.0)
Biancari (31) 2017 148 NA 33.8 31 2 (27.9)
3 (26.1)
Total/range – 2,852 63.7 24.8–52 16.5–47.6 2–10 (9.7–37)
ECMO, extracorporeal membrane oxygenation.
Articles founded from 
published literature
N=242
Articles not meet review 
inclusion criteria
N=175
Additional articles from 
references 
N=2
Articles with pediatric patients 
included or with duplicated 
clinical series
N=45
Articles without any detailed 
long-term outcomes
N=9
Articles clearly including post-
cardiotomy ECMO data
N=67
Selected articles 
N=13
Articles reviewed from 
published literature
N=15
Figure 1 Literature search and selection flow chart.
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evident that overall PC-ECMO patients have a favorable 
prognosis, with the vast majority maintaining a satisfactory 
clinical condition, limited readmission rate and favorable 
quality of life.
Discussion
The incidence of refractory PCS in adult cardiac surgical 
patients ranges from 0.5% to 1.5% (24,31,32). PCS is a rare 
but dreadful complication. The first PCS treatment step 
is pharmacologic. However, the overwhelming majority 
of PCS is unresponsive to high dosages of inotropes. 
Therefore, intra-aortic balloon pump support is frequently 
adopted, even if this strategy presents well-known 
limitations, particularly during active resuscitation (33). As 
a direct consequence, VA-ECMO has been increasingly 
considered and applied in PCS. Such a temporary MCS is 
a salvage therapy, often representing the only prompt and 
life-saving technique in refractory PCS cases. Although 
VA-ECMO support is a well-established and effective 
procedure in the presence of PCS, the in-hospital mortality 
rate is still high, with an unsatisfactory in-hospital outcome. 
In fact, the reported in-hospital survival has ranged from 
24.8% to 52% in several case series, a 1-year survival 
ranging from 16.5% to 47.6% and gradually ranging from 
almost 10% to 37% when the late survival is considered 
(20-30). These data clearly show how the majority of PC-
ECMO patients die during the hospitalization, showing 
a fall in the mortality rate after being discharged. This 
would mean that achieving the discharge might be one of 
the most important predictors of good long-term outcome. 
Therefore, it is clear that high in-hospital mortality remains 
the Achilles’ heel of ECMO. The importance of survival to 
discharge—and not just successful weaning—was illustrated 
by Ko et al., who studied 76 patients undergoing ECMO 
support for refractory PCS. Although 60.5% of this cohort 
was successfully weaned from ECMO, only 26.3% survived 
to discharge. However, all survivors showed New York 
Heart Association (NYHA) I and II functional class at 
32±22 months of follow-up (19).
However, the current literature doesn’t allow to make any 
substantial consideration regarding long-term outcomes. 
Lack of data and absence of standardized data collection 
made our analysis extremely undetailed and difficult to 
interpret. Under this light, the overall literature clearly 
shows a lot of cloudy aspects. von Bahr et al. reported a 
high risk of death, 15% within 90 days of hospital discharge 
increasing to 24% at long-term follow-up of 3 years (34). 
Table 2 Postcardiotomy ECMO major outcomes
Outcomes Details/results
NYHA class
Ko (19) NYHA class II or I
Doll (20) NYHA class II
Bakhtiary (22) NYHA class II or III
Unosawa (25) NYHA class I or II
Saxena (26) NYHA class I, II, III and IV
Khorsandi (27) NYHA class I–II
Readmission
Doll (20) Rate: 37.8%
Causes: routine cardiac investigations, 
pneumonia, non-cardiac-related surgical 
interventions
Bakhtiary (22) Rate: 60%
Causes: pneumonia, end-stage renal failure 
requiring dialysis
Chen (29) Mean N of readmissions: 0.68; 95% CI, 
0.60–0.78
Higher in PC patients support with ECMO
Expenditures
Chen (29) Greater in PC patients support with ECMO
Quality of life
Guihaire (30) Self-care without any limitations in all 
cases, minor problems considering other 
dimensions
Specific outcomes
Ko (19) Sudden death, pneumonia
Hsu (23) Cardiac arrest, severe infection
Unosawa (25) Cardiac events, heat stroke, ruptured iliac 
artery aneurysm, subarachnoid hemorrhage, 
pneumonia unknown cause
Saxena (26) End-stage heart disease
Guihaire (30) Major cardiac event, non-cardiac events
Bakhtiary (22) Congestive heart failure, pneumonia, end-
stage renal failure
NYHA, New York Heart Association; PC, post-cardiotomy; 
N, number; CI, confidence interval; ECMO, extracorporeal 
membrane oxygenation.
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In contrast, de Waha et al. showed 15.7% survival with 
satisfactory functional outcomes at 18 months in patients 
with refractory cardiogenic shock undergoing ECLS (35). 
Therefore, another crucial point that should be detailed 
better is the quality of life of survivors.
Other outcomes
The NYHA class is a remarkable scale for defining patient 
functional status (36). Six out of sixteen papers reported 
this parameter as part of long-term results in PC-ECMO 
patients. Doll et al. showed all survivors in NYHA class 
II at late follow-up (20). On the contrary, the experience 
presented by Saxena et al. (26). interestingly described a 
heterogenous functional status, which included patients 
in class III and IV. However, the overwhelming majority 
of these studies reported survivors in NYHA class I or II 
(20-30). This might lead to speculation that the PC-
ECMO survivors ,  once  overcoming the  ECMO-
related hospital course, may show a favorable long-term 
functional status. Guihaire et al. supported the latter 
finding by measuring the long-term quality of life (30). In 
this study, the health-related quality of life was assessed 
among PC-ECMO survivors 2 years after ECMO support 
using the EQ-5D survey (37) and the EQ visual analogue 
scale. No self-care limitations were found in any cases. 
Minor problems, however, were found considering other 
dimensions came out (e.g., mobility, usual activities, pain 
and anxiety) (38). Therefore, PC-ECMO survivors seem 
to achieve a long-term good functional status and quality 
of life. On the other hand, three papers included readmission 
rate in their analysis. The latter fluctuated from 37.8% to 
60%. Under this light, Chen et al. (29) observed a greater 
mean number of readmissions for any cause during the 
follow-up in patients who required ECMO compared with 
those who didn’t need the ECMO support after surgery. As 
a consequence, patients supported with ECMO for PCS 
might have an increased need of future hospitalizations. 
Chen et al. also found greater medical expenditure in 
PC-ECMO group during only the first year, which 
disappeared in the following checks. This finding might be 
related with the increase number of readmissions in this 
population, underlying the high disease burden amongst 
these patients. Finally, scant data are available regarding 
the specific causes of death or the new onset of morbidities 
in survivors. Nevertheless, infections and cardiac events 
might be considered the most common causes of death or 
morbidity (20-30).
Conclusions
In conclusion, the long-term survival in PC-ECMO 
seems to be strongly influenced by the early hospitalized 
critical phase, after which the survival slightly drops but 
remains satisfactory. Little is known, however, regarding 
other long-term outcome parameters after ECMO 
treatment in PC setting. The current lack of dedicated 
registries, limited data collection within studies and post-
discharge follow-up in PC-ECMO patients, and a few 
centers with this specific experience and high number of 
cases, are likely the most important causes for such poor 
information. Further investigations are urgently needed 
in order to better show post-discharge outcomes in adult 
patients submitted to PC-ECMO.
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